The Effects of Cardioprotective Antidiabetic Therapy on Microbiota in Patients with Type 2 Diabetes Mellitus—A Systematic Review
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24087184 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Ioana-Cristina Bica und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Doctoral School, "Carol Davila" University of Medicine and Pharmacy, 37 Dionisie Lupu, 020021 Bucharest, Romania. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Metformin, Cardiovascular Diseases. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
As the pathophysiologic mechanisms of type 2 diabetes mellitus (T2DM) are discovered, there is a switch from glucocentric to a more comprehensive, patient-centered management. The holistic approach considers the interlink between T2DM and its complications, finding the best therapies for minimizing the cardiovascular (CV) or renal risk and benefitting from the treatment‘s pleiotropic effects. Sodium-glucose cotransporter 2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) fit best in the holistic approach because of their effects in reducing the risk of CV events and obtaining better metabolic control. Additionally, research on the SGLT-2i and GLP-1 RA modification of gut microbiota is accumulating. The microbiota plays a significant role in the relation between diet and CV disease because some intestinal bacteria lead to an increase in short-chain fatty acids (SCFA) and consequent positive effects. Thus, our review aims to describe the relation between antidiabetic non-insulin therapy (SGLT-2i and GLP-1 RA) with CV-proven benefits and the gut microbiota in patients with T2DM. We identified five randomized clinical trials including dapagliflozin, empagliflozin, liraglutide, and loxenatide, with different results. There were differences between empagliflozin and metformin regarding the effects on microbiota despite similar glucose control in both study groups. One study demonstrated that liraglutide induced gut microbiota alterations in patients with T2DM treated initially with metformin, but another failed to detect any differences when the same molecule was compared with sitagliptin. The established CV and renal protection that the SGLT-2i and GLP-1 RA exert could be partly due to their action on gut microbiota. The individual and cumulative effects of antidiabetic drugs on gut microbiota need further research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Doctoral School, "Carol Davila" University of Medicine and Pharmacy, 37 Dionisie Lupu, 020021 Bucharest, Romania.
- Department of Diabetes, "Prof. Dr. N.C. Paulescu" National Institute of Diabetes, Nutrition and Metabolic Diseases, 030167 Bucharest, Romania.
- The Department of Gastroenterology, The Emergency University Hospital Bucharest, 050098 Bucharest, Romania.
- The Department of Diabetes, Nutrition and Metabolic Diseases, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
- The Gastroenterology Department, Ovidius University, 900527 Constanta, Romania.
ORCID-Profile: Ioana-Cristina Bica, Teodor Salmen, Roxana-Adriana Stoica, Anca Pantea Stoian
Zitieren
APA
Bica, I. C., Pietroșel, V. A., Salmen, T., Diaconu, C. T., Fierbinteanu Braticevici, C., Stoica, R. A., Suceveanu, A. I., & Pantea Stoian, A. (2023). The Effects of Cardioprotective Antidiabetic Therapy on Microbiota in Patients with Type 2 Diabetes Mellitus—A Systematic Review. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24087184
Vancouver
Bica IC, Pietroșel VA, Salmen T, Diaconu CT, Fierbinteanu Braticevici C, Stoica RA, et al. The Effects of Cardioprotective Antidiabetic Therapy on Microbiota in Patients with Type 2 Diabetes Mellitus—A Systematic Review. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24087184
BibTeX
@article{Bica2023,
author = {Bica, Ioana-Cristina and Pietroșel, Valeria-Anca and Salmen, Teodor and Diaconu, Cosmina-Theodora and Fierbinteanu Braticevici, Carmen and Stoica, Roxana-Adriana and Suceveanu, Andra Iulia and Pantea Stoian, Anca},
title = {The Effects of Cardioprotective Antidiabetic Therapy on Microbiota in Patients with Type 2 Diabetes Mellitus—A Systematic Review},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24087184}
}
EUVIMED